
    
      -  To determine safety, tolerability, maximum tolerated dose, and recommended phase II dose
           of venetoclax in combination with increasing cytarabine doses plus fixed dose
           mitoxantrone in subjects with a relapsed or refractory AML considered fit for intensive
           salvage therapy.

        -  To assess the preliminary efficacy of venetoclax in combination with increasing
           cytarabine doses plus fixed dose mitoxantrone in subjects with a relapsed or refractory
           AML considered fit for intensive salvage therapy.
    
  